| 保存条件 | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| 数量 | 货期:1-2天 |
| 供应商 | MedChemExpress LLC |
| CAS号 | 942507-42-8 |
| 规格 | 10 mM * 1 mL/25 mg/50 mg/100 mg |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 942507-42-8
MCE 国际站:AZ304
产品活性:AZ304 是一种 BRAF 双重抑制剂,有效抑制野生型 BRAF,突变型 BRAF (V600E) 和野生型 CRAF,IC50 值分别为 79 nM,38 nM 和 68 nM。AZ304 对其他激酶有显著抑制作用,如 p38 (IC50,6 nM),CSF1R (IC50,35 nM)。具有抗肿瘤活性。
研究领域:MAPK/ERK Pathway | Autophagy
In Vitro: AZ304 (1 nM-100 μM) potently reduces ERK phosphorylation (p-ERK), with a mean EC50 of 65 nM in the V600E mutant BRAF containing melanoma cell line A375, and EC50s of 52 nM, 60 nM in the wild type BRAF melanoma cell line SK-MEL-31 with and without EGF.AZ304 also potently inhibits p-p38 in both BRAF genetic statuses cell lines.
AZ304 (0, 0.1, 1, 10, 100 μM, 48 and 72 hours) dose-dependently inhibits the growth of RKO, HT-29, DiFi, and Caco-2, with GI50s of 4.539 μM, 3.896 μM, 4.987 μM, 1.763 μM (48 hours) and 0.5032 μM, 0.3887 μM, 0.6354 μM, 0.3772 μM (72 hours), respectively.
AZ304 (2 μM, 36 and 48 hours) decreases BRAF, p-ERK, p-AKT and p-mTOR levels, increases p-EGFR in both BRAF V600E mutant and BRAF wild type cells. AZ304 down-regulates p-EGFR, inhibits p-ERK, more potently suppresses BRAF, ERK, AKT and mTOR signalling pathways in combination with C225.
相关产品:Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Anti-Cancer Compound Library | Autophagy Compound Library | Oxygen Sensing Compound Library | Ferroptosis Compound Library | Glutamine Metabolism Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Doramapimod | GW 5074 | Ro 5126766 | AZ 628 | GDC-0879 | ZM 336372 | Agerafenib | Raf inhibitor 1 | L-779450 | MCP110 | Raf inhibitor 2 | Sorafenib (D3)
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪前沿的制药及生命科学研究进展,为您提供全球前沿的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。